Locally advanced pancreatic cancer: A review of local ablative therapies

Research output: Contribution to journalReview articleAcademicpeer-review

Abstract

Pancreatic cancer is typically characterized by its aggressive tumor growth and dismal prognosis. Approximately 30% of patients with pancreatic cancer present with locally advanced disease, broadly defined as having a tumor-to-artery interface >180°, having an unreconstructable portal vein or superior mesenteric vein and no signs of metastatic disease. These patients are currently designated to palliative systemic chemotherapy, though median overall survival remains poor (approximately 11 months). Therefore, several innovative local therapies have been investigated as new treatment options for locally advanced pancreatic cancer (LAPC). This article provides an overview of available data with regard to morbidity and oncological outcome of novel local therapies for LAPC.
Original languageEnglish
Article number16
JournalCancers
Volume10
Issue number1
DOIs
Publication statusPublished - 2018

Cite this